SG Americas Securities
SPRY icon

SG Americas Securities’s ARS Pharmaceuticals SPRY Stock Holding History

SG Americas Securities’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140K Buy
+17,534
New +$151K ﹤0.01% 2955
2026
Q1 		– Sell
-76,203
Closed -$888K – 3671
2025
Q4 		$888K Buy
76,203
+66,098
+654% +$643K ﹤0.01% 2111
2025
Q3 		$102K Sell
10,105
-15,196
-60% -$218K ﹤0.01% 3077
2025
Q2 		$442K Sell
25,301
-11,125
-31% -$161K ﹤0.01% 1757
2025
Q1 		$458K Sell
36,426
-14,776
-29% -$178K ﹤0.01% 1853
2024
Q4 		$540K Sell
51,202
-7,102
-12% -$99.5K ﹤0.01% 1267
2024
Q3 		$845K Sell
58,304
-53,288
-48% -$634K ﹤0.01% 1216
2024
Q2 		$950K Buy
111,592
+99,986
+862% +$887K 0.01% 1325
2024
Q1 		$119K Buy
+11,606
New +$86.5K ﹤0.01% 2421
2022
Q1 		– Sell
-11,405
Closed -$76K – 3400
2021
Q4 		$76K Sell
11,405
-2,053
-15% -$16.7K ﹤0.01% 3137
2021
Q3 		$134K Buy
13,458
+6,917
+106% +$171K ﹤0.01% 3508
2021
Q2 		$202K Buy
+6,541
New +$210K ﹤0.01% 2335
2021
Q1 		– Sell
-12,900
Closed -$598K – 3534
2020
Q4 		$598K Buy
+12,900
New +$431K ﹤0.01% 1852

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

SG Americas Securities's SPRY Position: Q2 2026 in Review

SG Americas Securities opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 17,534 shares worth $140K. The stake represents ﹤0.01% of the portfolio and ranks #2955 among its holdings. This is a return to the name: SG Americas Securities previously reported a position in SPRY as recently as Q4 2025.

SG Americas Securities first reported a position in SPRY in Q4 2020 and has held it in 13 quarters since. The position peaked at $950K in Q2 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • SG Americas Securities held 17,534 shares of ARS Pharmaceuticals worth $140K as of Q2 2026.
  • ARS Pharmaceuticals was a new SG Americas Securities position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2955 holding.
  • SG Americas Securities first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 13 quarters since.
  • SG Americas Securities's ARS Pharmaceuticals position peaked at $950K in Q2 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.